和誉-B(02256.HK)：FGFR2/3抑制剂ABSK061治疗儿童软骨发育不全的IND获FDA许可

Core Viewpoint - The company announced that its subsidiary, Shanghai Heyu Biomedical Technology Co., Ltd., has received FDA approval for the clinical trial application of its selective small molecule FGFR2/3 inhibitor ABSK061 for treating children with achondroplasia (ACH) [1] Group 1 - The FDA has granted permission for the IND of ABSK061, which is a significant milestone for the company [1] - The approval is complemented by the previously awarded Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) by the FDA, which will facilitate the overseas clinical development of ABSK061 [1]